Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
DuPont De Nemours, Inc Among Today's Trending Stocks
11:17am, Tuesday, 06'th Jul 2021
Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified DuPont De Nemours, Inc among others.
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Jul 2021
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Why Spero Therapeutics Stock Is Up 15% Today
01:12pm, Thursday, 01'st Jul 2021
The small biopharma's work has captured the attention of a much bigger player.
SPRO Stock Price Increases Over 25% Pre-Market: Why It Happened
06:58am, Thursday, 01'st Jul 2021
The stock price of Spero Therapeutics, Inc. (Nasdaq: SPRO) increased by over 25% pre-market. This is why it happened.
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
06:46pm, Wednesday, 30'th Jun 2021
Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. S
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
04:01pm, Tuesday, 15'th Jun 2021
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commerciali
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:35pm, Friday, 28'th May 2021
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializi
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript
04:48am, Sunday, 09'th May 2021
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2021 Results - Earnings Call Transcript
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:26pm, Friday, 30'th Apr 2021
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:31pm, Wednesday, 31'st Mar 2021
CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript
09:15pm, Thursday, 11'th Mar 2021
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q4 2020 Results - Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
06:56pm, Thursday, 11'th Mar 2021
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 11.69% and -41.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
04:07pm, Thursday, 11'th Mar 2021
Tebipenem HBr advancing towards NDA submission in the second half of 2021
Will Spero Therapeutics, Inc. (SPRO) Report Negative Q4 Earnings? What You Should Know
01:38pm, Monday, 08'th Mar 2021
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021
08:30am, Wednesday, 03'rd Mar 2021
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commerciali
